Cardiac complexities: all we have to know about our heart
Keywords:CVDs, CHD, IHD, HTN, ECG, Tobacco use, diabetes
The leading cause of death worldwide is cardiovascular disease (CVD). In 2019, an estimated 17.9 million people died from CVDs, or 32% of all deaths worldwide. Over 75% of deaths from cardiovascular disease occur in low- and middle-income countries. Many CVDs can be prevented by identifying behavioural risk factors like poor diet, smoking, tobacco use, hyperlipedema, obesity, harmful alcohol use, and lack of physical activity. A group of ailments known as cardiovascular diseases (CVDs) include myocardial infarction, cerebrovascular disease, coronary heart disease, rheumatic heart disease, congenital heart disease, and other conditions. Additionally, heart attacks and strokes account for four out of every five CVD deaths, and one-third of these deaths occur in people under the age of 70. Frequently, the basic blood vessel disease goes unnoticed for years. A heart attack or stroke could be the first symptom of an underlying condition. Pain or discomfort in the middle of the chest, as well as discomfort or pain in the left shoulder, arms, jaw, elbows, or back, numbness, and weakness, are all signs of a heart attack. Additionally, the individual could experience respiratory problems or fatigue, numbness, and back pain. Additionally, the person may have shortness of breath or difficulty breathing, nausea or vomiting, faintness and light-headedness, sweating, shivering, and a change in skin colour. Women are more likely than men to have nausea, breathlessness, jaw or back discomfort, and vomiting. An array of imaging studies and laboratory testing are used to diagnose CVDs. The patient's medical history and family history, physical examination, risk factors, and combining these findings with the outcomes of treatments and tests make up the majority of a diagnosis The World Health Organization (WHO) encourages governments to manage, prevent, and monitor cardiovascular diseases (CVDs) by increasing global strategies to minimise the incidence, mortality, and morbidity of these diseases. Some of the typical tests performed to diagnose cardiovascular diseases include: Blood tests and chest X-rays include ECG or EKG, Echocardiogram, Coronary angiogram, MRI, CCTA, and other tests. Reduced risk factors, the cessation of tobacco use, reduced salt intake, increased consumption of fruits and vegetables, well planned physical activity, and abstinence from alcohol abuse have all been demonstrated to reduce the incidence of CVDs . Increasing the capacity of the health system to care for people with CVD, distributing standards of care, and monitoring disease patterns and trends to inform national and international initiatives. The consequences of behavioural risk factors, which are linked to important socioeconomic determinants and drivers including income, ageing, and urbanisation, may manifest in people as raised blood sugar, elevated blood pressure, elevated blood lipids, obesity, and overweight.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Ferri FF. Coronary artery disease. In: Ferri's Clinical Advisor 2022. Elsevier; 2022. https://www.clinicalkey.com. Accessed March 8, 2022.
Dr. PayalKohli, M.D., FACC — By Valencia Higuera — Updated on July 5, 2022 9.Rhian M. Touyz
Basile J, et al. Overview of hypertension in adults. https://www.uptodate.com/contents/search. Accessed July 22, 2022
Understanding blood pressure readings. American Heart Association. https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings. Accessed July 18, 2022.
Debra Sullivan, Ph.D., MSN, R.N., CNE, COI — By Brindles Lee Macon — Updated on August 4, 2017
Jameson JL, et al., eds. Cardiovascular collapse, cardiac arrest, and sudden cardiac death. In: Harrison's Principles of Internal Medicine. 20th ed. McGraw Hill? 2018. https://accessmedicine.mhmedical.com. Accessed Nov. 9, 2020.
Bonow RO, et al., eds. Cardiac arrest and sudden cardiac death. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Elsevier; 2019. https://www.clinicalkey.com. Accessed Nov. 9, 2020.
Patel K, Hipskind JE. https://www.ncbi.nlm.nih.gov/books/NBK534866/#!po=1.56250
Fugate JE, Rabinstein AA. Life after cardiac arrest: better with time. (https://pubmed.ncbi.nlm.nih.gov/24291509/) Resuscitation. 2014 Feb;85(2):157-8. Accessed 6/6/2022
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Stout KK, et al. 2018 AHA/ACC Guideline for the management of adults with congenital heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;
American Heart Association. About Congenital Heart Defects. (https://www.heart.org/en/health-topics/congenital-heart-defects/about-congenital-heart-defects) Accessed 8/10/2021.
Pierpont ME, et al. Genetic basis for congenital heart disease: Revisited: A scientific statement from the American Heart Association. Circulation. 2018; https://www.news-medical.net/health/Cardiovascular-Disease-Diagnosis.aspx
Kastrup, J. Gene therapy and angiogenesis in patients with coronary artery disease.ExpertRev.Cardiovasc. Ther. 2010, 8, 1127–1138. [CrossRef] [PubMed]
Gunaseeli, I.; Doss, M.X.; Antzelevitch, C.; Hescheler, J.; Sachinidis, A. Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr. Med. Chem. 2010, 17, 759– 766.[CrossRef] [PubMed]
Barile, L.; Messina, E.; Giacomello, A.; Marban, E. Endogenous cardiac stem cells. Prog.Cardiovasc. Dis. 2007, 50, 31–48. [CrossRef] [PubMed
Cardiovascular and renal outcomes with empagliflozin in heart failure. N EnglJMed. 2020;383:1413–1424. [PubMed]
Graham, M.J.; Lemonidis, K.M.; Whipple, C.P.; Subramaniam, A.; Monia, B.P.; Crooke, S.T.; Crooke, R.M. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 2007, 48, 763–767
Pham, A.Q.; Patel, Y.; Gallagher, B. LCZ696 (angiotensin-neprilysin inhibition): The new kid on theheart failure block? J. Pharm. Pract. 2015, 28, 137–145.
Burnier M. Antihypertensive combination treatment: state of the art. CurrHypertens Rep. 2015;17:51. https://doi.org/10.1007/s11906-015-0562-0. [PubMed]
eart Protection Study Collaborative Group.Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. 45, 645–654 a(2007).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002; 360:7–22. doi: 10.1016/S0140-6736(02)09327-3CrossrefMedline
Pedersen TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, HaghfeltT.Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study(4S).Am J Cardiol. 1998; 81:333–335. doi: 10.1016/s0002-9149(97)00904-CrossrefMedline.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.